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                                             ABSTRACT 
 
South Africa is ranked fourth on the list of 22 high-burden TB countries in the world. 
Intensifying the prevalence of TB in South Africa is the high TB/HIV co-infection rate, with 44% 
of new TB patients testing positive for HIV. This burden is intense for rural communities due to 
poverty and return of people with TB/HIV co-infection who previously migrated for 
employment. In rural South Africa, TB is the leading cause of mortality in HIV-infected persons, 
but limited information is available about predictors of death. This study measures TB 
treatment outcomes in Rixile clinic and assesses predictors of TB mortality.  
Rixile HIV clinic is based in Tintswalo hospital, Acornhoek, Bushbuckridge, Mpumalanga 
province. This current study uses secondary data collected through a prospective cohort study 
conducted by PHRU and RADAR from March 2003 to March 2008 on 3 to 6 monthly intervals. 
Chi-square and logistic regression statistical tests were used to assess predictors of TB 
Mortality.  
TB mortality among study participants was 62.5% during the pre-ARV rollout period (March 
2003- October 2005), and treatment completion was 31.7%. Some 5.8% participants 
interrupted treatment during the pre-ARV rollout period as compared to 4.5% during the ARV 
rollout period (November 2005- March 2008). TB mortality among study participants was 7.5% 
during ARV rollout and treatment completion increased to 84.4%. Factors associated with TB 
mortality were age (p=0.006), sex (p=0.017), BMI (p< 0.001), marital status (p=0.004), education 
(p=0.03), alcoholic beverages consumption (p=0.04), and ARV treatment (p<0.001). However, 
only age, sex, and ARV treatment were found to predict TB mortality.  
The proportion of TB treatment completion was higher and TB mortality was lower during ARV 
roll-out compared to pre-ARV roll-out. Being at the age of 40 to 75 years, not being on ARV 
treatment and male sex predicts TB mortality in this population. There is a need to expand ARV 
treatment and intensify TB care services for older people, particularly males living with HIV in 
this rural community. 
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                       ABBREVIATIONS AND ACRONYMS 
 
TB= Tuberculosis  
MDR-TB=Multi-Drug Resistant-Tuberculosis  
XDR-TB= Extensive Drug Resistant-Tuberculosis 
HIV=Human Immunodeficiency Virus  
AIDS=Acquired Immunodeficiency Syndrome  
BMI= Body Mass Index 
ARV=Antiretroviral 
ART=Antiretroviral therapy 
WHO=World Health Organization 
DOTs= Directly Observed Therapy Support 
PHRU= Perinatal HIV Research Unit 
RADAR= Rural AIDS and Development Action Research  
CRF= Case Report Form 
CCF= Clinical Care Form 
CI= Confidence Interval 
RR=Relative Risk 
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1 INTRODUCTION  
1.1 BACKROUND  
Tuberculosis (TB) is estimated to cause at least three million deaths per year worldwide [1]. In 
South Africa, TB is a major public health problem. According to the World Health Organization 
(WHO) the country is ranked fourth on the list of 22 high-burden TB countries in the world [1]. 
The incidence rate was estimated at 940 per 100,000 people in 2006 compared to 333 per 
100,000 in 1996 [1]. Constraining the progress to combat TB in South Africa is the high TB/HIV 
co-infection rate, with 44% of new TB patients testing positive for HIV [1]. This burden of 
TB/HIV co-infection is worsened in rural communities by poverty [2], and return of people with 
TB/HIV co-infection who previously migrated to urban areas for employment [3]. The impact of 
this high prevalence of TB/HIV co-infection in rural South Africa can be reduced by concomitant 
TB and HIV treatment [4].  
The advent of HIV and TB treatment is reported to improve survival among HIV/TB patients 
enrolled for both treatments [4]. To some extent this benefit of TB/HIV concomitant therapy 
can be explained by DOT support, [5,6] sensitivity of TB strain to the drugs used for treatment 
[5] and HIV stage of the person on treatment [7]. TB treatment outcomes are improved in 
people who take the therapy under the support of DOT [5,6], with 84% of people taking TB/HIV 
treatment reported to have completed treatment [6]. Despite improved treatment completion 
and low mortality presented by a previous study conducted in Kwazulu-Natal province of South 
Africa [6], death due to TB in HIV co-infected persons is still high in rural South Africa [8]. 
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Demographic factors, social factors, lifestyle factors, and clinical factors were reported to be 
the predictors of death due to TB among people co-infected with HIV and those infected with 
TB only [7,9].   
Depletion of CD4+ cells in HIV-infected persons increases the risk of both primary and 
reactivation tuberculosis [10]. HIV-positive people infected with TB are fifty times more likely to 
develop active TB in their lifetime than people who are HIV-negative [2]. Interruption of TB 
treatment increases the risk for development of drug resistance strains of TB which are hard 
and expensive to treat [5]. Two strains of drug-resistant TB are Multidrug resistant tuberculosis 
(MDR TB) and Extensively drug resistant TB (XDR TB). MDR TB is diagnosed when there is in 
vitro resistance of M. tuberculosis against, at least, rifampicin or isoniazid [11,12]. XDR-TB is the 
MDR TB strain which is also resistant to one of the fluoroquinoles and one of the injectable 
drugs such as kanamycin, capreomycin or amikacin [12]. Drug resistant TB commonly arises 
from exogenous infection rather than activation of primary infection in HIV-infected persons 
[13].  HIV is not associated with development of drug-resistant TB [14], but high prevalence of 
drug-resistant TB in HIV-infected persons is primarily due to impaired immunity which confers 
them high susceptibility to infection [10,15]. Infection with drug-resistant strains increases the 
risk of TB mortality, particularly in HIV-infected persons; [15,16] with XDR TB causing 98% 
mortality [16]. 
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1.2 STUDY SITE SETTINGS 
HIV and TB treatments are free of charge for HIV-infected persons in Tintswalo hospital. 
Participants enrolled in the wellness study conducted by Rural AIDS and Development Action 
Research (RADAR) and Perinatal HIV Research Unit (PHRU) in Rixile clinic took HIV and TB 
treatments in Tintswalo hospital. The ARV programme in Rixile clinic (Tintswalo hospital) 
started in October 2005.  
TB and HIV treatments in Tintswalo hospital are prescribed in line with South African standard 
treatment guidelines [11]. Regimen 1 treatment for active TB, is isoniazid, Rifampicin, 
pyrazinamide, and ethambutol for two months (intensive phase), then isoniazid and rifampicin 
alone for a further four months (continuation phase).   If the organism is known to be sensitive, 
ethambutol need not be used. Regimen 2 is given to patients previously treated for TB and 
consists of isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin for the first two 
months to three months, and rifampicin, isoniazid and ethambutol for the further five months. 
Regimen 1 treatment for HIV consists of two nucleosides reverse transcriptase inhibitors, that is 
stavudine, lamivudine, and a non-nucleoside reverse transcriptase inhibitor, either efavirenz or 
nevirapine. Regimen 2 consists of two alternative nucleoside reverse transcriptase inhibitors, 
which are zidovudine and didanosine plus the protease inhibitor combination that is 
lopinavir/ritonavir.    
DOTS (directly observed treatment short course) have been implemented in Tintswalo hospital. 
An important element of the strategy is the support and encouragement offered to TB patients 
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for the entire six- to eight-month treatment period, where patients are directly observed taking 
their medication at the clinic.    
1.3 LITERATURE REVIEW 
TB is primarily a disease of the respiratory system which spreads when the TB patients expel 
the droplets by sneezing, spitting and coughing and the people nearby inhale the droplets and 
become infected with mycobacteria, mainly Mycobacterium tuberculosis [12]. When 
mycobacteria reach the alveoli of the lung, they invade and replicate within the endosomes of 
alveolar macrophages. Infection can result in latent TB or active disease which clinically can be 
classified as extra-pulmonary or pulmonary TB [12]. Latent TB is asymptomatic and Symptoms 
for active TB are chronic cough, blood-tinged sputum, night sweats, and weight loss [12]. World 
Health Organization (WHO) estimates that a single TB patient with active disease if not treated 
can infect on average 10-15 people every year [2]. On laboratory test (Ziehl-Nielson Staining), 
TB can be smear-negative or smear-positive [12]. Smear-negative pulmonary TB is defined by 
South African TB Control Program by two positive cultures of M. tuberculosis with confirmed 
identical spoligotype; and smear-positive as a positive sputum smear confirmed with a second 
positive smear or culture of M. tuberculosis. [17] 
HIV infection is characterized by progressive depletion of CD+ cells that eventually lead to AIDS, 
as defined by opportunistic infections [18]. Responsible for the massive depletion of memory 
CD4+ T-cells are on-going viral replication and virus-induced cell death [18]. Despite rapid 
depletion of CD4+ T cells early during HIV infection, most opportunistic infections typically 
cause complications only after extended periods of HIV disease progression [10]. HIV increases 
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the likelihood of people acquiring new TB infection [18]. It also promotes both the progression 
of latent TB infection to active disease and relapse of the disease in previously treated patients 
[18]. For TB/HIV co-infected persons ARV’s and TB treatments are given concurrently to 
improve immunity and the outcomes of TB treatment in South Africa [11]. Drug-interactions 
and side-effects in TB/HIV co-infected people taking HIV and TB curative therapies have been 
reported [19]; however, the concomitant treatment of TB/HIV co-infection is reported to have 
improved adherence to treatment which is important for preventing the emergence of drug 
resistance TB. [16]   
In 1991, the 44th World Health Assembly set two key targets for global tuberculosis (TB) control 
to be reached by the year 2000: 70% case detection of acid-fast bacilli smear-positive TB 
patients under the DOTS strategy recommended by WHO and 85% treatment success of those 
detected [2].  Studies reported that WHO’s target of treatment success is achievable in people 
with smear-positive TB even in under-resourced developing countries [20].  
In Hlabisa (South Africa) a twice-weekly directly observed therapy (DOT) for TB in HIV-infected 
and non-infected persons have shown to be effective. At six months of follow-up; 71% of 
participants were cured, 3% completed treatment without being cured, 2% transferred out and 
only 2% treatment failure was reported. The study concluded that a twice-weekly rifampicin-
containing drug regimen given under DOT cures most adherent patients irrespective of HIV 
status and previous TB treatment history [5].  
A study conducted in rural South Africa (Kwazulu-Natal) among 119 TB/HIV co-infected persons 
reported successful integration of TB and HIV treatment. After 12 months of concurrent HIV 
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and TB treatment by home-based, modified directly observed therapy (DOT); 84% of enrolled 
participants reported to have completed treatment and 11% died while on treatment. 
Concurrent home-based therapy resulted in excellent adherence to TB and HIV treatment [6].   
In a randomized control-trial conducted in Malawi (Karonga) and Zambia (Lusaka) HIV-negative 
and HIV-positive 996 and 198 participants respectively were followed-up from September 1996 
to October 1998. During the follow-up 230 participants died, and 216 of these were HIV-
positive, while at baseline only less than 70% of enrolled participants both in Karonga (56%) and 
Lusaka (67%) were HIV-positive. HIV-positive participants were receiving only anti-tuberculosis 
treatment and they were not receiving HIV treatment. One of the factors found to be the 
predictor for mortality was age. Other predictors of mortality were low Body Mass Index (BMI), 
low level of haemoglobin, and more advanced clinical stages of HIV at baseline [7]. 
In Uganda a study enrolled a cohort of 105 male and 109 female HIV-infected adults receiving 
treatment for initial episodes of culture confirmed TB between March 1993 and March 1995. In 
this study favorable outcomes were defined as cured or alive while unfavorable outcomes were 
not being cured or dead. At the end of one year of follow-up there was no difference in the 
likelihood of experiencing a favorable outcome (RR 1.02, 95 CI 0.89-1.17). While differences 
existed between males and females with HIV-associated TB at baseline, the outcomes at one 
year after initiation of TB treatment were similar [21]. 
A study conducted in rural South Africa (Agincourt) from 1992 to 2000 reported higher PTB/HIV 
death rate for males than females for all ages combined (RRMH=2.48, 95% CI 1.53-4.04, 
p<0.001) [22]. This was not true for all ages as female mortality was not different from male 
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mortality before age 25 years. The excess male mortality was restricted to older age groups (25-
34, 35-44, and 45-55 years). The median age at PTB/HIV deaths among males was 38 years. 
Death due to the co-infection PTB/HIV was 24.9% (95% CI, 20.0-29.8%), the proportion in men 
(32.1%) being higher than that in women (16.9%).  
Associations between TB mortality and increased age, treatment delay, and defaulting 
treatment in HIV-infected persons were reported in a study conducted in Ghana [9]. In this 
study, mortality was associated with increased age (p < 0.001), residence in a rural area (p < 
0.05), sputum smear-negative disease (p < 0.01), prolonged symptom duration prior to initial 
diagnosis (p < 0.05), and defaulting treatment (p < 0.05). The study concluded that HIV is 
strongly associated with TB mortality in persons with co-infection, however, increased age, 
residence in rural area, sputum smear-negative disease, more prolonged symptom duration 
prior to initial diagnosis and defaulting treatment causes increased TB mortality in HIV-infected 
persons. 
The outcomes of TB treatment are improved in HIV-infected persons taking TB treatment under 
the support of DOT supporter [5,6]. There is generally no disparity on the outcomes of TB 
treatment between males and females, [21, 22] except on people at 25 years of age and older 
[22].  In HIV-infected and non-infected persons; age, Body Mass Index (BMI), low level of 
haemoglobin, sex and more advanced clinical stages of HIV at baseline were reported to be 
predictors of TB mortality [7,26].  Age was further reported to be a predictor of TB mortality 
among with other factors such as residence in rural area, sputum smear-negative disease, 
defaulting TB treatment and prolonged symptom duration prior to initial diagnosis [9].  
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Although some people enrolled in these studies were co-infected with HIV/TB, they were 
receiving only TB therapy, and the predictors of TB mortality were explained in people receiving 
TB therapy only [7,9].                   
1.4 DEFINITIONS  
Case of Tuberculosis: A patient in whom tuberculosis has been confirmed by bacteriology or 
diagnosed by a clinician [23]. 
WHO HIV staging: World Health Organization (WHO) HIV clinical stages [24] 
1. Completed treatment 
The participant completed initiation phase and continuation phase of TB treatment, and it is 
not known whether is cured or not.  
2. Interrupted treatment 
The participant reports failure to take TB treatment for two months or more consecutively or 
fails to appear to the clinic for two months or more consecutively without notifying the data 
collectors after the first follow up visit to the clinic.  
3. TB Mortality      
Death while on TB treatment with confirmed TB at the time of death.  
4. Transfer out. 
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A participant was formally referred to another health facility from the clinic during the follow 
up period.                                                                                                                                              
1.5  PROBLEM STATEMENT   
Antiretroviral given with TB treatment improves survival in HIV-infected TB patients [4]. 
Concomitant TB and HIV treatments in TB/HIV co-infected persons under DOT observation were 
readily available from October 2005 in Tintswalo hospital. However, the researcher is unaware 
of another study measuring the outcomes of TB treatment among patients receiving TB 
treatment only and those also receiving TB/HIV treatments in Tintswalo Hospital. In particular, 
to measure TB treatment outcomes defined as completed treatment, interrupted treatment, 
death while on treatment with the reported cause of death to be TB (TB mortality), and transfer 
out in the period before and during ARV roll-outs in this rural community of South Africa.  In 
rural South Africa, TB is the leading cause of mortality in HIV-infected TB patients [8], but 
limited knowledge exists about risk factors for death [6,8,22]. One study examined pattern of 
PTB/HIV mortality in males and females [22]. Mortality rate disparity was apparent in male and 
female patients at and older than 25 years of age, with males having higher mortality rate; [22] 
however, it is uncertain whether demographic factors (sex, age, BMI), social factors (marital 
status, education, employment status), lifestyle factors (alcohol consumption habits, smoking 
habits) and clinical factors (ARV treatment) predicts TB mortality in TB/HIV co-infected persons.   
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1.6 JUSTIFICATION FOR THE STUDY 
Studies call for expansion of ARV treatment to reach those in need, earlier ARV treatment 
initiation, and routine screening of TB in South Africa, [8] and the concomitant TB/HIV therapy 
is reported to improve survival in co-infected persons [4]. Understanding of the impact of 
concurrent TB and ARV treatment in TB treatment outcomes is important if ARV and TB 
treatment are to be prioritized during health planning for resource allocation. The specific 
reasons for TB mortality are important in order to improve treatment. In Malawi (Karonga) and 
Zambia (Lusaka) age, low BMI, low level of haemoglobin, and advanced stages of HIV at 
baseline were significant risk factors for mortality in the population of HIV-infected and HIV 
non-infected TB patients [7].  In another study, age, residence in rural area, sputum smear-
negative disease, defaulting TB treatment and prolonged symptom duration prior to initial 
diagnosis were found to be associated with TB mortality [9]. In South Africa, Identification of 
factors associated with TB mortality in HIV-infected persons will guide Public Health policy for 
screening of factors associated with TB mortality prior to TB treatment in order to improve TB 
treatment completion and prevent TB mortality.           
1.7  RESEARCH QUESTION 
What are the TB treatment outcomes and factors associated with TB mortality in adult HIV-
infected persons receiving TB treatment in a rural HIV clinic in South Africa?  
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1.8  STUDY OBJECTIVES  
1.8.1 Overall objective 
To determine outcomes of adult (≥18 years) patients treated for TB attending a rural HIV clinic 
in South Africa. 
 
1.8.2 Specific objectives 
1.8.2.1  To measure TB treatment outcomes defined as completed treatment, interrupted 
treatment, TB mortality, and transfer out among adult patients receiving TB treatment.   
1.8.2.2 To identify factors associated with TB mortality in adult TB patients receiving TB 
treatment in a rural HIV clinic. 
 
2 METHODOLOGY 
2.1 DESCRIPTION OF THE PRIMARY DATASET 
Perinatal HIV Research Unit (PHRU) and Rural AIDS Research and Development Action Research 
(RADAR) conducted the wellness study in Rixile clinic, Tintswalo hospital, Bushbuckridge. The 
study was on HIV and TB. Hence, all enrolled participants were HIV positive, and some of the 
enrolled participants were co-infected with TB and they were receiving TB treatment.  Data for 
the study was collected from March 2003 to March 2008 on 3 to 6 months intervals in all 
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enrolled participants. PHRU and RADAR data collectors used the case report form (CRF) to 
collect socioeconomic, demographic, TB treatment, and HIV information. [Appendix 1]      
This study analyzed secondary data on the basis of the information already collected in the 
PHRU and RADAR study. Exposure and outcome variables required by the current study were 
available on the dataset provided by PHRU and RADAR data managers. TB mortality was 
reported for people on stage four of HIV infection only. Therefore, HIV-staging could not be 
regressed as a predictor of TB mortality. Almost 75% of data on CD4 cell count was not 
available in the dataset. Therefore the confounding effect of cd4 cell count was not assessed on 
factors associated with TB mortality, and CD4 could not be regressed as a predictor for TB 
mortality. 
2.2  STUDY DESIGN 
The study applied a prospective cohort design. Data of HIV-infected persons on TB treatment 
who have at least one follow up clinic visit at Rixile clinic in the period March 2003 to March 
2008 was analyzed. ARV treatment started in 2005 in Rixile clinic; therefore this study divided 
the follow up period into first (March 2003 to October 2005) and the second (November 2005 
to March 2008) term with the purpose of describing TB treatment outcomes in the period 
before and during ARV roll-out. Proportions of outcomes were stratified into two terms: the 
first term, before antiretrovirals (ARV’s) were dispensed in Rixile clinic, and the second term 
when ARV’s were provided. The study design was also suitable for assessing the variation in TB 
treatment outcomes depending on the term. The cumulative proportions of TB treatment 
outcomes were also calculated with the numerator being the total number of each outcome 
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throughout the follow-up period (March 2003 to March 2008) and the denominator being the 
total number of enrolled participants throughout the follow-up period (March 2003 to March 
2008).   
2.3  STUDY AREA 
Rixile clinic is an HIV clinic in Tintswalo hospital. Tintswalo hospital is based in the village of 
Acornhoek in Bushbuckridge. Bushbuckridge is located in Mpumalanga province of South Africa. 
Tintswalo hospital is right at the border of former Lebowa and Gazankulu homelands, but, the 
hospital fell under the Gazankulu homeland during the era of homelands in South Africa. From 
the year 1996 onwards, the hospital was under the then Northern province (now Limpopo 
province) and in the year 2006, the hospital was relocated to Mpumalanga province. Rixile clinic 
is amongst the clinic dispensing ARV’s in Bushbuckridge. Participants were receiving an 
integrated TB/HIV treatment in Rixile clinic. The clinic also serves as the research center for 
national and international research.               
2.4 STUDY POPULATION 
The study participants were HIV infected tuberculosis patients attending Rixile HIV clinic from 
March 2003 to March 2008. 
Inclusion criteria: -HIV-infected persons diagnosed with TB. 
                               -Both sexes (males and females) 
                              -18 years and older 
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Exclusion criteria: -HIV-infected persons without tuberculosis. 
                               -HIV-infected TB patients not on TB treatment. 
                              -HIV-infected patients on TB preventive therapy. 
                                                                                                                                                                                                                            
2.5 SAMPLE SIZE CALCULATION 
Table 1: Estimate of the precision from data sample size 
 
 
 
 
                                                          
Equation:  ∆=Zα/z √P(1-P)/n
 
The original data comprised of 2221 HIV-infected participants enrolled from March 2003 to 
March 2008. One thousands and ten (1010) of the enrolled participants were placed in TB 
curative treatment. The study sample size was the extracted 1010 participants with TB and 
receiving TB curative treatment therapy from the 2221 participants. However due to missing 
values, analysis was restricted to 785 participants. 
At worst, the precision that can be achieved from the data of 785 participants at 95% 
confidence interval is within the range of three percent [(0.015*2)*100] [Table 1].     
P-value (P) Sample precision estimate (∆) 
0.01 0.006 
0.02 0.010 
0.03 0.012 
0.04 0.014 
0.05 0.015 
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2.6 STUDY VARIABLES 
2.6.1 The outcome variables  
1. Completed treatment 
2. Interrupted treatment 
3. TB mortality 
4. Transfer out  
  
2.6.2 Exposure variables 
 
2.6.2.1 Demographic factors 
 
Age 
 Three categories generated following the normal distribution of the variable. The categories 
are: 18-30 years, 31-40 years, and 41 to 75 years. 
sex 
Males and Females 
BMI 
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<18.5, ≥18.5-<25, ≥25-<30, and ≥30 [25] 
 
2.6.2.2 Social factors 
 
Marital status 
Unmarried, divorced/widowed/separated and married 
Occupational status 
Unemployed, students, and employed 
Education   
No education, Primary, secondary, and tertiary  
 
2.6.2.3 Lifestyle factors  
 
Consumption of alcoholic beverages 
Non-consumers and consumers  
Smoking habits 
Non-smokers and smokers 
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2.6.2.4 Clinical factor 
 
ART treatment 
Treated (Yes) and not treated (No) 
2.7  DATA COLLECTION METHODS AND TOOLS 
The case report form (CRF) designed by PHRU and RADAR was used for data collection. PHRU 
and RADAR data collectors received training to prior data collection. The unique identity 
number for each participant in CRF was used and this identity number was similar to the 
identity number in the clinical care form (CCF). Data was collected from two different sources; 
the clinical consultations and laboratory results. The information from these two different 
sources was recorded in the CRF [see Appendix 1]. An interview was arranged for a date three 
months after the participant consented to the study. The CRF would be opened once the 
patient consented to participate in the study and the information from the CCF of that patient 
would be transferred to the CRF. Transferring of data from the CCF to the CRF was checked 
twice by different people to assess for error which might have occurred during the transferring 
process. The data collector conducting interviews during the follow up period differed from the 
person who enrolled the participant into the study. The participants were seen in the period 
between 3 and 6 months. The follow-up interviews were conducted when participants were 
coming for treatment in Rixile clinic.  
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2.8 DATA PROCESSING METHODS AND DATA ANALYSIS. 
Data management was conducted by the use of Microsoft Office Access by PHRU and RADAR. 
For this secondary data analysis study, data was received in Microsoft Office Excel format. Stata 
version 9.0 was used for data cleaning and statistical analysis. Variables for the study were 
selected before importing data into Stata version 9.0. Data cleaning in Stata version 9.0 
included assessing quality of data in terms of missing values, and internal consistencies of 
responses.  
Proportions were used to describe categorical variables stratified across the first and second 
term follow up periods. The total numbers of TB patients on treatment were computed at the 
beginning of each term. Variables were categorized before assessment of their association with 
TB mortality.     
The five year (2003-2008) data was analyzed prospectively, with the TB treatment outcomes of 
the first and second term carried out separately. Frequencies and proportions of TB treatment 
outcomes (completed treatment, interrupted treatment, TB mortality and transfer out) were 
computed. The denominator for calculation of proportions in each term was the total number 
of TB patients on treatment at the beginning of the term. The cumulative proportions for each 
outcome were carried out from the total number of participants in each outcome to the total 
number of participants enrolled throughout the follow up period. Histogram was used to 
explain and compare various outcomes over the two terms [Figure 1].   
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Chi-square test was carried out to assess the association between TB mortality and 
demographic factors (sex and age groups), social status (marital status, occupational status and 
educational level), lifestyle factors (alcohol consumption and smoking habits), and clinical factor 
(ARV treatment). The significance level was at chi-square value for one degree of freedom and 
5% p-value. The results of the chi-square were presented on the table with the corresponding 
number and percentage of participants in each variable [table 3]. 
Logistic regression was carried out to construct the model of TB mortality against various 
suspected predictors of TB mortality. The following factors were included in the model: 
demographic factors (sex, age, BMI), social factors (marital status, education and occupational 
status), lifestyle factors (alcoholic beverages consumption and smoking habits), and clinical 
factor (ARV treatment).  Univariate and multivariate models were constructed; the significance 
level of both models was at 5% with 95% confidence interval not crossing zero.  The outcomes 
of the model were reported with relative risk [RR], and 95% confidence intervals. The outcomes 
of the univariate and multivariate models were presented in the table with corresponding 
number of participants in each category and the proportion of people died with the reported 
cause of death to be TB [table 4]. Logistic regression models were constructed to assess for 
interaction by regressing the created interaction terms and the significance of interaction was 
reported at 5% significance level. Mantel Haenszel test was used to assess for confounding 
effects. The significance of Mantel Haenszel test was set at 5% significance level. Logistic model 
assumptions were assessed. 
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2.9 ETHICAL CONSIDERATIONS. 
Approval for the primary study by PHRU and RADAR was given by the ethics committee of the 
University of the Witwatersrand.   
Informed consent was given by all participants enrolled in the primary study conducted by 
PHRU and RADAR. 
Approval for this study was obtained from the University of Witwatersrand Ethics Committee 
(Approval Number: R14/49). [APPENDIX B] 
Data was used for the purpose of the study only. Care and caution were exercised when data 
was handled. Careful considerations were given to anonymity, confidentiality and privacy issues 
surrounding the primary purpose which the data was collected for.  
The individuals in the study sample were identified by the unique identifier. Any personal 
identifiers were removed prior the data being given to the researcher for analysis and as such, 
the researcher was not able to identify the individuals in the sample.  
3 Results 
3.1 Study participants description 
One thousands and ten (1010) HIV-infected TB patients receiving TB treatment in Rixile clinic 
from March 2003 to March 2008 were eligible for inclusion in the study. A total of 225 
participants had more than 50% missing observations in the variables of interest to the study 
and were excluded from the analysis. Therefore, only 785 participants were included in the 
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analysis. A total of 131 participants included in the analysis reported a history of TB: 118 were 
treated for TB once before, 10 two times and 3 three times. Data was collected from March 
2003 onwards. The ARV treatment started in October 2005, and therefore, the periods of 
follow-up were divided into first term (March 2003 to October 2005) and second term 
(November 2005 to March 2008) representing the pre-ARV and ARV roll-out periods 
respectively. The demographic, social, lifestyle and clinical characteristics of HIV/TB co-infected 
participants are shown in table 2.                              
Demographic factors: At beginning of the first term, three hundred and sixty-three (68%) of 
participants were females; mean age at presentation was 35 years. Most participants (57%) 
were at the ages 31 to 40 years, while 17% were at the ages of 41 to 75 years. At the beginning 
of the second term, some 20% of participants were at the ages of 18 to 30 years and 38% at the 
ages of 41 to 75 years, and 40% of enrolled participants were males. During the first term 74 
participants were underweight (BMI less than 18.5) compared to 99 participants during the 
second term [table 2]. However, majority of participants presented with normal body weight 
(BMI ≥18.5-<25) during both terms [table 2]. Throughout the follow-up time (March 2005 to 
March 2008) the race component was solely black/African.     
Social factors: Over 50% of literate participants reported a secondary education and less than 
4% tertiary education at the beginning of both the first and the second terms. Among 
categories of employment status, similar proportions were observed in each category 
(Employed/Unemployed/Students) during the first and the second terms [table 2]. More than 
80% of participants (86%) were unemployed compared to 13% reported to be employed during 
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both terms [table 2]. Only one percent of participants were students at the beginning of both 
terms. Lower proportion reported to be unmarried (28%) during the first term compared to 
36% during the second term [table 2].  Some 43% of participants reported to be widowed or 
divorced or separated during the first term compared to 34% during the second term [table 2]. 
There was a slightly difference in the proportion of those who reported to be married during 
the first (30%) and the second (29%) terms [table 2].     
Lifestyle factors: Around 16% of participants reported to be consuming alcoholic beverages at 
the beginning of the first term compared to 20% at the beginning of the second term. Some 
22% and 6% of participants reported to be consuming alcoholic beverages during the first and 
the second terms respectively [table 2].  Amongst those who reported to be consuming 
alcoholic beverages 87% were males and 13% were females throughout the follow-up period.  
At the beginning of the first term some 24% of participants reported to be smoking at least one 
cigarette a day. Throughout the follow-up time, around 21% of participants reported to be 
smoking at least one cigarette a day and 65% of those who reported this were at 40 to 75 years 
of age. Proportion of women (6%) smoking at least one cigarette a day was less compared to 
men (44%) throughout the follow-up period.  
Clinical factors: At presentation during the second term the percentage of participants in stage 3 of 
HIV infection dropped by 1% compared to the first term; in contrast the percentage of those who 
were in stage 1 of HIV infection was higher by 1% during the second term compared to the first 
term [table 2]. Around 19% of participants were on ARV treatment during the first term compared 
to 58% percent during the second term [table 2].    
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Table 2: Descriptive statistics of 785 participants receiving TB and HIV treatments in Rixile 
clinic during the 1
st
 Term (March 2003 to October 2005) and the 2
nd
 Term (November 2005 to 
March 2008).                                                                                                                                                                                 
Factor Variable Category 
First Term 
(March 2003- October 
2005) 
N (%) 
Second Term 
(November 2005- March 
2008) 
N (%) 
 
 
 
Demographic 
Factors 
 
Age (years) 
18-30 33 (15) 106 (19) 
31-40 92 (43) 200 (35) 
41-75 90 (42) 264 (46) 
Sex 
Female 178 (67) 285 (57) 
Male 89 (33) 211 (43) 
BMI 
<18.5  74 (28) 99 (19) 
≥18.5-<25 95 (36) 215 (41) 
≥25-<30 20 (8) 66 (13) 
≥30 72 (28)   144 (27) 
Social Factors 
Marital 
Status 
Unmarried 44 (28)  177 (36) 
Divorced/wid
owed/separat
ed 
68 (43) 166 (34) 
Married 47 (29) 147 (30) 
Employment 
Status 
Employed 22 (13) 65 (13) 
Unemployed 146 (86) 423 (86) 
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3.2 TB treatment outcomes 
3.2.1 Completed treatment 
Treatment completion increased from 31.7% during the first term to 84.4% during the second 
term [Figure 1]. Treatment completion was high among participants at the age of 31 to 40 
years at 42% followed by participants at the ages of 41 years to 75 years (32%). Females (57%) 
Student 1 (1) 3 (1) 
Education 
No Education 31 (18) 93 (19) 
Primary 50 (29) 84 (17) 
Secondary 90 (52) 297 (60) 
Tertiary 2 (1) 20 (4) 
Lifestyle Factors 
Alcoholic 
beverages 
Consumptio
n 
Non-drinkers 163 (78) 519 (94) 
Drinkers 45 (22) 31 (6) 
Smoking 
habits 
Non-smokers 194 (98) 541 (99) 
Smokers 4 (2) 5  (1) 
Clinical Factors 
ARV 
Treatment 
Yes 56 (19) 270 (58) 
No 240 (81) 200 (42) 
WHO HIV 
staging 
Stage 1 30 (11) 53 (12) 
Stage 2 97 (35) 149 (33) 
Stage 3 108 (40) 179 (39) 
Stage 4 37 (14)  75 (16) 
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than males (43%) completed the treatment throughout the follow-up time. Around 38% of 
participants who never married completed treatment compared to 35% of married participants 
and 27% of widowed/divorced/separated participants. One hundred and eighty-one of 423 
participants reported to be unemployed during the second term completed treatment. 
Participants who reported secondary education (62%) have completed treatment than 
participants with primary (18%) or tertiary education (6%). Only less than 25% of participants 
taking at least one cigarette a day (20%) and those consuming alcoholic beverages (23%) 
reported to have completed treatment.  
 
3.2.2 Interrupted treatment 
Treatment interruption was 4.5% during the second term compared to 5.8% during the first 
term [Figure 1]. Treatment interruption was higher (59%) among participants at 41 to 75 years 
of age. Lower proportion of participants 18 to 30 years (10%) interrupted treatment compared 
to those at the ages of 31 to 40 years (60%) and at ages of 41 to 75 years (30%). The proportion 
of women (64%) who interrupted the treatment was higher than for men (36%).  Higher 
proportion of Widowed/separated/divorced participants interrupted the treatment (50%). 
Around 30% and 9% of Alcoholic beverages consumers and those who are illiterate reported to 
have interrupted treatment respectively.     
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Figure 1: TB treatment outcomes in HIV/TB co-infected participants receiving HIV and TB 
treatments during the first term (March 2003 to October 2005) and during the second term 
(November 2005 to March 2008) in Rixile clinic. 
 
 
 
 
 
 
 
 
3.2.3 Mortality   
 
 
 
The proportion of TB mortality was 62.5% during the first term and 7.5% during the second 
term [Figure 1]. Fifty-four percent of TB mortality occurred to females. The highest rate of 
mortality (51%) occurred to participants between 31 to 40 years of age. TB mortality was high 
in participants reported to be divorced/widowed/separated (39%) compared to married (34%) 
and unmarried participants (27%). Sixty-five percent of TB mortality occurred in participants 
who reported to have obtained secondary education. Around 23% of the total participants died 
reported to be alcoholic beverages consumers. Calculated from the cumulative proportion 
value of TB mortality [table 3], TB mortality rate was at 2640 per 100 000 people in HIV-
infected persons throughout the follow-up time (March 2003 to March 2008).     
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3.2.4 Transfer out 
None reported to have transferred out of Rixile clinic during the first term [Figure 1]. During the 
second term 83% of the participants transferred out were females and they were at the ages of 
41 to 75 years. Those who transferred out were mainly unemployed, had primary education 
and reported to be not smoking cigarettes and not consuming alcoholic beverages.   
Table 3: Proportions of TB treatment outcomes in participants receiving TB and HIV 
treatments in Rixile clinic from March 2003 to March 2008.   
*Total number of number of outcome throughout the follow-up time/total number of participants 
Of the 785 participants remained for analysis, around 248 were reported to be still on 
treatment at the end of the study, the outcomes of 234 participants were reported to have died 
of other HIV related causes and not TB. Those who reported treatment ongoing on those who 
died of HIV related causes were excluded on the denominator when calculating the proportion 
of TB treatment outcomes. During the first term, the proportion of mortality was 62.5% and 
treatment completion was 31.7%, however during the second term proportion of mortality fell 
to 7.5% and the treatment completion rate rose to 84.4% [Figure 1]. Mortality during the 
 
Outcomes 
1
st
 Term (March 2003-October 
2005) 
2
nd
 Term (November 
2005-March 2008) 
Cumulative 
Proportion 
(CP)* Number Proportion Number Proportion 
Completed 
treatment 
33 31.7 168 84.4 66.3 
Interrupted 
treatment 
6 5.8 9 4.5 5.0 
TB Mortality 65 62.5 15 7.5 26.4 
Transfer out 00 0.0 7 3.5 2.3 
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second term (7.5%) was low compared with 62.5% during the first term [Figure 1]. Treatment 
completion was higher during the second term (66.3%) as compared to the first term (31.7%).  
3.3 Factors associated with TB mortality 
The chi-square test of association was carried out to assess the association between TB 
mortality and demographic factors (age, sex, BMI), social factors (marital status, occupational 
status, education), lifestyle factors (alcoholic beverages consumption and smoking habits), and 
clinical factor (ARV treatment). All mortality cases were reported on participants on stage 4 of 
HIV staging, therefore clinical stages could not be included to assess if it’s a predictor for TB 
mortality. Table 4 represents the results of chi-square test of association.  Demographic factors 
(age, sex, BMI), social factors (marital status, education), lifestyle factor (alcoholic beverages 
consumption) and clinical factor (ARV treatment) showed significant association with TB 
mortality.   
 
Table 4: Chi-square results on factors associated with TB mortality in participants receiving TB 
and HIV treatments in Rixile clinic from March 2003 to March 2008. 
Factor Variable Category N (%) Chi2 Value P>Chi2 
Demographic 
Factors 
Age 
(years) 
18-30 139 (18) 
10.3 0.006 31-40 292 (37) 
41-75 354 (45) 
Sex Female 463 (61) 5.7 0.017 
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Male 300 (39) 
BMI 
<18.5  173 (22) 
86.4 <0.001 
≥18.5-<25 310 (39) 
≥25-<30 86 (11) 
≥30 216 (28) 
Social Factors 
Marital 
Status 
Unmarried 221 (34) 
10.9 0.004 
Divorced/widowe
d/separated 
234 (36) 
Married         194 (30) 
Employme
nt Status 
Employed                 87  (13) 
2.9 0.2 Unemployed 569 (86) 
Student 4 (1) 
Education 
No Education 124 (19) 
9.3 0.03 
Primary 134  (19) 
Secondary 387 (58) 
Tertiary 22 (3) 
Lifestyle Factors 
Alcoholic 
beverages 
Consumpt
ion 
Non-drinkers 682 (96) 
5.9 0.04 
Drinkers 28 (4) 
Smoking 
habits 
Non-smokers 735 (99) 
0.8 0.4 
Smokers 9 (1) 
Clinical factor 
ARV 
treatment 
Yes 326 
86.6 <0.001 
No 440 
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3.4 Predictors of TB mortality  
Univariate and multivariate logistic regression models were constructed to assess the 
predictors of TB mortality. All factors which showed significant association with TB mortality on 
chi-square test were modeled in the univariate model to assess if they are predictors of TB 
mortality.  
3.4.1 Univariate analysis 
Univariate analysis on the relationship between demographic factors and TB mortality showed 
an association with demographic factors (age, sex, BMI), social factor (education) and clinical 
factor (ARV treatment). In the analysis, those at the age of 31 to 40 years and those 41 to 75 
years were at higher risk (relative risk [RR] 2.2, 95% CI (1.3-3.6)) and (relative risk [RR] 2.2, 95% 
CI (1.2-4.1)) of dying of TB respectively compared to lower age category (18-30 years). From the 
Social factors, education was significant; participants who reported primary education (relative 
risk [RR] 0.5, 95% CI (0.2-0.9)) and secondary (relative risk [RR] 0.5, 95% CI (0.3-0.9)) were at 
lower risk of TB mortality compared to participants with no formal education. Participants who 
were not on ARV treatment were at higher risk (relative risk [RR] 11.0, 95% CI (6.1-19.8)) of 
dying of TB compared to participants on treatment. 
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Table 5: Univariate and multivariate logistic regression analysis of predictors of TB mortality 
in 785 participants receiving TB and HIV treatments in Rixile HIV clinic from March 2003 to 
March 2008. 
Factor Variable Category 
Tota
l 
(N) 
TB 
mortalit
y (%) 
Univariate  Multivariate 
Relative 
Risk 
(RR) 
95% CI 
Relative 
Risk 
(RR) 
95% CI 
 
 
 
Demographic 
factors 
 
 
 
Age (years) 
18-30 139 28.4 1 1 1 1 
31-40 292 45.7 2.2 (1.3, 3.6) 2.2 (0.8, 5.8) 
41-75 354 25.9 2.2 (1.2, 4.1) 3.2 (2.4, 7.7) 
Sex 
Female 463 45.7 1 1 1 1 
Male 300 54.3 1.1 (1.1, 2.6) 8.7 (3.3, 22.8) 
BMI 
    <18.5 173 17.6 1 1 1 1 
≥18.5-<25 310 4.7 3.2 (1.5, 6.9) 2.0 (0.7, 5.5) 
≥25-<30 86 0.0 - - - - 
≥30 216 32.9 0.3 (0.2, 0.6) 0.4 (0.2, 1.2) 
Social factors 
Marital 
Status 
Divorced/w
idowed/se
parated 
234 39.2 1 1 1 1 
Married 194 33.8 1.6 (0.9, 2.7)   
Unmarried 221 27.0 2.4 (1.4, 4.2)   
Education 
No 
Education 
124 13.8 1 1 1 1 
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3.4.2 Multivariate analysis 
The variables which were significant in univariate models were included in the final multivariate 
model: demographic (age, sex, BMI), social factor (education), and clinical factor (ARV 
treatment). 
Being at 41 to 75 years of age was associated with the higher risk (relative risk [RR] 3.2, 95% CI 
(2.4 -7.7)) of dying of TB as compared to lower age category (18-30 years) when adjusted for 
age, sex, BMI,  education,  and ARV treatment. Males were nine times more likely to die of TB 
(relative risk [RR] 8.7, 95% CI (3.3-22.8)) compared to females in HIV-infected TB patients when 
adjusted for age, BMI, education, and ARV treatment. Participants who were not on ARV 
treatment were at higher risk of dying of TB (relative risk [RR] 23.2, 95% CI (8.7 -62.3)) 
compared to those who were on ARV treatment when adjusted for age, sex, BMI, education.  
 
Primary 134 20.0 0.5 (0.2, 0.9) 0.2 (0.05, 1.0) 
Secondary 387 65.0 0.5 (0.3, 0.9) 0.4 (0.1, 1.3) 
Tertiary 22 1.3 2.8 (0.4, 23.2) - - 
Lifestyle 
factor 
Alcoholic 
beverages 
Consumptio
n 
Non-
drinkers 
682 75.4 1 1 1 1 
Drinkers 28 24.6 1.6 (0.8, 3.3)   
 
Clinical factor 
 
ARV 
Treatment 
Yes 326 30.8 1 1 1 1 
No 440 3.9 11.0 (6.1, 19.8) 23.2 (8.7, 62.3) 
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4 DISCUSSION    
The study analyzed a five year cohort of 785 HIV-infected TB patients receiving TB treatment 
and/or HIV treatment in Rixile clinic from 2003 to March 2008. Although 19% of participants 
were on HIV treatment prior to October 2005, HIV treatment in Rixile clinic started in October 
2005.  Those who reported to be on HIV treatment before October 2005 received treatment 
from other clinics or hospitals. During the second term (during ARV rollout), the proportion of 
mortality was lower compared to the first term (before ARV rollout). In contrast, the proportion 
of treatment completion was low during the first term compared to the second term. 
Demographic factors (age, sex) and a clinical factor (ARV treatment) were associated with TB 
mortality in HIV-infected TB patients receiving TB treatment and HIV treatment or TB treatment 
only in Rixile clinic from March 2003 to March 2008. 
The proportion of each TB treatment outcome was expressed as the percentage using the total 
number of a particular TB treatment outcome to the total number of enrolled participants 
during a particular term. Treatment completion during the first term was lower compared to 
treatment completion during the second term, and participants at 31 to 40 years of age 
completed treatment than those at younger (18-30) and older (41-75) age categories. The 
proportion of TB treatment completion during the second term was similar to the proportion of 
TB treatment completion reported in a study conducted in rural South Africa, Kwazulu-Natal. 
[6] In contrast, the proportion of people died while on treatment during the second term was 
slightly lower than the proportion reported in the previous study. [6] TB mortality case 
definition used in this study was different from the one used in the previous study, and this 
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explains disparity on proportions of TB mortality reported in this study and the study conducted 
in Kwazulu-Natal. [6] Slightly higher proportion of women died with the reported cause of 
death as TB while on TB treatment and this is in contrast with the higher male mortality on 
people at the age of 25 years and older reported by the previous study [22]. Higher proportion 
of females interrupted treatment than males.  Non-adherence to TB can cause TB strains to be 
resistant to the primary TB drugs such as isoniazid and rifampicin, [5] drug resistant strains is 
associated with high mortality in infected patients, particularly those co-infected with HIV [15]. 
Although drug-resistance is not analyzed in the study, higher proportion of TB mortality in 
females could be perhaps associated with higher TB treatment interruption.  In the previous 
study conducted in Hlabisa, slightly higher proportion reported to have transferred out 
compared to the proportion reported to have transferred out from Tintswalo hospital in the 
period between November 2005 and March 2008. [5]     
The chi-square test predicted association between TB mortality and demographic factors (age, 
sex, BMI), social factors (marital status, education), lifestyle factor (smoking habits) and a 
clinical factor (ARV treatment).  These factors were further included in the logistic model to 
assess if they are the predictors of TB mortality. Considering the variables modeled by use of 
logistic regression, being at the age of 41 to 75 years of age was associated with death from TB 
in HIV-infected persons. Although the study conducted in other developing countries, Malawi 
and Zambia, was on HIV-infected and non-infected TB patients, the findings that age predicts TB 
mortality is in line with the results presented in this study. [7] Increased age was further 
reported as a predictor of TB mortality in HIV-infected TB patients [9]. Although BMI was 
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presented as predictor for TB mortality in the previous study, [7] in this study such association 
was not significant.  Despite higher mortality reported in females when compared to males; 
males were at higher risk of TB mortality compared to females. This finding confirms the 
findings presented in the study conducted in South Africa where sex was the predictor of TB 
mortality [26]. ARV treatment predicts TB mortality in HIV-infected persons, with higher TB 
mortality in those not receiving ARV treatment compared to those receiving ART treatment. 
Although the study did not assess whether ARV treatment predicts TB mortality; after the six 
months of ARV Treatment initiation, the study reported reduced mortality due to TB in HIV-
infected persons TB patients [27].   
LIMITATIONS OF THE STUDY 
Data was not having information on drug-resistance TB. Drug-resistance TB cannot be cured 
with standard treatment (first-line drugs) and is often associated with high mortality [15,16]. 
Although several risk factors were examined, there is probably considerable residual 
confounding. CD4 counts, which would be a better measure of the degree of immune 
suppression was available with considerable missing data and was not included in the analysis. 
There was a considerable sufficient data for analysis on WHO HIV staging; however, TB 
mortality occurred to participants who were on stage four (4) only; as a result WHO HIV staging 
could not be assessed as a predictor of TB mortality.  The incomplete dates of study enrollment 
and the exit limited the study to perform analyses such as survival analysis. Amongst the 
possible TB treatment outcomes, cure was not included, therefore, cure rate would  be 
assumed from patients who completed the treatment, and perhaps not all patients completed 
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the treatment were cured. Like other cohort studies, loss to follow up has been the great 
limitation of the study. Loss to follow up during the study resulted in considerable missing 
information in various variables in the data. This study as a secondary data analysis study does 
not have control over data quality, collection methods and missing information.  The problem 
of under-reporting of TB mortality may arise where a proportion of patients with “missing 
outcome” have in fact died with the reported cause of death as TB. 
 
5 CONCLUSION AND RECOMMENDATIONS 
Participants who started treatment during the ARV roll-out in Rixile clinic completed treatment 
than those started treatment before the ARV roll-out. Death due to TB in HIV-infected persons 
was lower during the ARV roll-out. Although there are considerable differences on definitions, 
the proportion of TB mortality during the ARV roll-out was lower compared to what the 
previous study reported.  Concurrent TB/HIV treatment could be the notable approach to 
combat TB and HIV and to improve survival by preventing mortality in co-infected persons in 
this rural community of South Africa.  
Participants at the ages of 41 to 75 years were at higher risk of death due to TB than those at 
other age groups. Males were at increased risk of death with the reported cause of death as TB 
when compared to females. This finding supports the call for age screening prior to TB 
treatment in HIV-infected persons with the purpose of intensifying the treatment to patients in 
this age category, particularly males. The expansion of ART could reduce death due to TB in 
HIV-infected TB patients.  Death due to TB in HIV-infected persons is lower than the reported in 
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this rural community, and expansion of concurrent TB and HIV treatment could be the solution 
in prevention of death due to TB in HIV-infected persons in this rural community of South 
Africa.  
PLAN FOR UTILIZATION AND DISSEMINATION OF RESULTS. 
Copies of the final report will be submitted to Faculty of Health Sciences, Wits University. 
Results of the study will be presented to Wits University school of Public Health. Other copies of 
the final report will be available to Tintswalo hospital (Rixile clinic), and Department of Health 
(South Africa) on request. The results will be ready for publishing in a leading journal.  
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